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Hypercalcaemia is a common medical problem, can be a manifestation of many diseases and, when severe, can 
represent a life-threatening medical emergency. 
Making the correct diagnosis is important 
to prevent unnecessary investigations and 
parathyroidectomies. At Sultan Qaboos University 
Hospital, Oman, we have recently seen five patients 
with severe hypercalcaemia (calcium ≥3.5 mmol/L), 
most of whom had been misdiagnosed for months 
or even years. The clinical examination, evaluation 
of the fasting serum calcium, phosphate, creatinine 
and 24-hour urine calcium levels together with a 
review of their radiographs accurately predicted the 
pathophysiology of the disorder and successfully 
guided our investigative procedures well before the 
results of hormone assays became available.
Case Reports
Details of the five patients together with their 
presenting serum calcium levels are shown in 
Table 1.  In addition to the well recognised symptoms 
of a high calcium level, namely constipation, 
polyuria, polydipsia, nausea and vomiting, they 
were all anorexic with marked weight loss ranging 
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aBstract: Hypercalcaemia, a common medical problem, can be a manifestation of various diseases. When 
severe, it can represent a medical emergency. Correct diagnosis is important to prevent unnecessary investigations 
and parathyroidectomies. We here present five patients with severe hypercalcaemia, most misdiagnosed for months 
or years before being referred to Sultan Qaboos University Hospital, Oman. We report how clinical examination, 
evaluation of fasting serum calcium, phosphate, creatinine and 24-hour urine calcium levels together with a review 
of their radiographics predicted the pathophysiology of the disorder and guided investigative procedures before 
hormone assays results were available.
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from 6–15 kg over 4–8 months, irrespective of the 
underlying disease. Muscle weakness was profound 
in patients 1 and 2, and mental confusion was severe 
in patients 1, 4 and 5.
Some patients had additional clinical problems. 
Patients 2 and 4 had been successfully treated 
for hypertension (with atenolol and lisinopril 
respectively) for more than 5 years and patient 4 
also had type 2 diabetes with proteinuria 3.6 mg/24 
hours (normal range 0.05–0.1) and a monocloncal 
gammopathy. Patient 5 had a breast carcinoma, had 
been treated at another hospital for 2 years and was 
terminal upon arrival at our hospital.
 The biochemistry of the patients at presentation 
was as follows, with data from the patients’ initial 
fasting sample shown in Table 2. Note the low 
serum phosphate and normal creatinine levels in 
patients 1 and 5 and normal phosphate and elevated 
creatinine levels in patients 2, 3 and 4.  The patients’ 
hormone profiles are shown in Table 3.  Parathyroid 
hormone (PTH) levels were dramatically increased 
in patient 1, but suppressed in the others including 
patient 5 with metastatic breast cancer. The 
parathyroid hormone-related peptide (PTH-rP) 
level was increased in patient 5, but suppressed 
in all the other patients. Levels of 1,25 dihydroxy 
vitamin D3 (OH)2D3 were increased in all patients.
Patients’ radiographs helped to diagnose the 
cause of the hypercalcaemia in 4 of the 5 patients. 
Patient 1 had the classical X-ray findings of 
primary hyperparathyroidism (HPT) with severe 
osteoporosis [Figure 1a] and bone mineral density 
(BMD) of 600 g/cm2 confirming severe osteoporosis 
[Figure 1b]. The neck ultrasound, magnetic 
resonance imaging (MRI) and parathyroid scans 
confirmed a parathyroid adenoma [Figure 1c].  In 





Presenting Symptoms / Details
1 23 5.2 Three year history of polyuria, polydipsia, fatiguability, constipation, 
electrocardiogram abnormality labelled Wolff-Parkinson-White. Renal stone 
requiring lithotripsy in another hospital.
Admitted with confusion, disorientation, marked weight loss (30 kg over 
previous 6 months), conjunctivitis, calcific keratitis, myopathy, hypotension, 
oliguria, osteoporosis.
Electrocardiogram:  remarkable ST depression with T-wave inversion 
consistent with metabolic electrocardiogram (K 2.3, Mg 0.23)
2 80 4.2 Weakness, weight loss (20 kg in 6 months), myopathy, difficulty in walking
3 45 3.5 Cough, weight loss (12 kg in 6 months), constipation
4 60 4.9 Presented with coma to medical services in neighbouring country, 
treated with hydration and bisphosphonate. Discharged with diagnosis of 
hypercalcaemia of unknown aetiology
Admitted with confusion, weight loss (10 kg in 6 months)
5 45 4.9 Advanced metastatic breast cancer
Admitted with confusion, vomiting, abdominal pain, weight loss (20 kg in 6 
months )
Table 2:  Patients bone profile, serum calcium (Ca), phosphorus (Phos), alkaline phosphatase (ALP), 

















1 5.2 0.4 600 98 20
2 4.2 1.88 94 313 5
3 3.5 1.1 101 284 4
4 4.9 1.1 73 333 4.8
5 4.9 0.35 200 90 10
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patient 2, the computed tomography (CT) scan 
revealed a left axillary lymph node which was not 
palpable clinically [Figure 2a]. He underwent a 
diagnostic lymph node biopsy. An X-ray and CT 
scan of the chest of patient 3 showed bilateral hilar 
lymphadenopathy [Figure 3a], while the chest X-ray 
of patient 4 was normal. In patient 5, the chest 
showed metastases to the lung [Figure 5].
Histology confirmed the diagnosis in every 
patient. Patient 1 had a benign parathyroid 
adenoma [Figure 1d]. In patient 2, the bone marrow 
and lymph node biopsy revealed a large β-cell 
lymphoma [Figure 2b]. In patient 3, with a positive 
Mantoux test, caseating granulomas were seen 
on a bronchial biopsy specimen [Figure 3b]. Non-
caseating granulomas consistent with sarcoidosis 
were seen on the renal biopsy in patient 4 [Figure 
4], whose Mantoux test was negative. In addition, 
Table 3: Patients presenting parathyroid hormone (PTH), parathyroid hormone related peptide (PTH-rP) 
and 1,25 dihydroxy vitamin D3 (1,25 vit D) levels are indicated with their normal ranges (NR).






1 268 - 214
2 0.7 1.0 411
3 0.5 1.0 164
4 0.1 0.2 243
5 0.1 10 200
Figure 1a: Patient 1- Spinal film showing osteopenia, and hand X-ray revealing subperiosteal cortical bone erosion
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his bone marrow revealed clusters of plasma cells 
consistent with myeloma (not shown).  The lymph 
node biopsy in patient 5 confirmed metastatic 
breast cancer (not shown).
As to the management of the hypercalcaemia, 
when a patient’s serum calcium concentration is 
≤3 mmol, then treatment should be aimed solely at 
managing the underlying disorder.  Patients should 
also be advised to take plenty of oral fluid.  If there 
are symptoms and signs of acute hypercalcaemia as 
in patients 1, 2, 4 and 5 (Table 1) and serum calcium 
is >3 mmol, then a series of urgent measures should 
be instituted as outlined in Table 4.1 Our patients 
were treated for their underlying diseases: patient 
1 with severe hyperparathyroidism, was hydrated 
aggressively with saline and given calcitonin 
and bisphosphonate to inhibit bone resorption. 
His severe electrolyte disturbance was managed 
with IV potassium and magnesium for 3 weeks 
until the calcium level had fallen to 3 mmol, 
and the electrocardiogram (ECG) readings had 
normalised [Figure 1e].  He then underwent right 
parathyroidectomy and right hemithyroidectomy. 
Patient 2 was treated for the large β-cell lymphoma 
with anti-CD20 antibody (rituximab). Patient 3 was 
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Figure 1b: Patient 1- Bone mineral density scan 
confirming severe osteoporosis
Figure 1c: Patient 1- Ultrasound, magnetic resonance, computer tomography and parathyroid scans showing a 3 x 2 
cm vascular adenoma
Table 4: Management of severe hypercalcaemia. Patients 
with myeloma and some cases with granulomatous 
disorders will respond to steroid suppression. 
Management of Acute Hypercalcaemia
1.  Hydration
           Saline (0.9%) infusion, 2-6 L over 24 hours with K 
and/or Mg 
           supplementation
2.  Inhibition of bone resorption
          Calcitonin
               4 IU/kg to 8 IU/kg q 12 hours sc or IM x 1 to 2 days
          Bisphosphonate 
               Pamidronate (60 to 90 mg oer 4 hours IV) or
               Zoledronate (4 mg over 15 min IV)
3.  Low calcium diet and avoid sunshine
4.  Dialysis (in renal failure)
5.  Treat underlying disease
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TB for 9 months. Patient 4 was treated with steroids 
for sarcoidosis and melphalan for myeloma, while 
patient 5 received chemotherapy for the breast 
cancer [Figure 5].
With treatment of the underlying diseases, the 
serum calcium and 1,25(OH)2 D3 levels and the 
renal function returned to normal in patients 1, 2, 3 
and 4  [Figure 6a, b,& c].  The serum creatinine level 
was slightly high above the normal range in patient 2 
due to his diabetic nephropathy. The serum calcium 
level returned to normal in patient 5, but she died 6 
months later from her advancing metastatic cancer.
As regards parathyroid hormone (PTH) and 
Figure 1d: Patient 1 - Histology reveals an intrathyroidal 
benign parathyroid adenoma.
Figure 1e: Patient 1 - Admission ECG revealing severe 
ST segment depression and T wave inversion and 
considerable improvement after 3 weeks medical 
treatment
Figure 2a: Patient 2 - Computed tomography chest scan 
showing a 4 x 2 left axillary node.
Figure 2b: Patient 2 - Axillary node biopsy revealing 
a lymphocyte predominant Hodgkin's disease β-cell 
lymphoma.
Figure 3a: Patient 3 - Computed tomography chest scan 
with bilateral hilar lymphadenopathy.
Figure 3b: Patient 3 - Transbronchial biopsy showing a 
caseating granuloma consistent with tuberculosis.
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parathyroid hormone related peptide (PTH-
rP) excess, the 24-hour urinary calcium values 
are above normal and increase with rising 
hormone levels. Low values with normal serum 
creatinine levels suggest a diagnosis of familial 
hypocalciuric hypercalcaemia. This disorder results 
from an inactivating mutation of the calcium receptor 
(Ca-R) gene causing mild hyperparathyroidism not 
requiring surgical intervention.2 
Discussion
The hypercalcaemia observed in these 5 patients 
was caused by raised circulating levels of 3 different 
hormones; PTH (patient 1), PTH-rP (patient 5) and 
1,25(OH)2D3 (patients 2, 3, and 4).  PTH and PTH-
rP share the same receptors causing hypercalcaemia 
and hypophosphataemia in the same way. Both 
stimulate renal 1α hydroxylase activity and raise 
circulating 1,25(OH)2D levels thus increasing 
intestinal calcium absorption.1,3 This additional 
load of calcium cannot be excreted as both 
hormones increase tubular calcium reabsorption. 
Hypercalcaemia results, but urinary calcium levels 
are only modestly increased and kidney function 
spared.3-5 The net contribution of bone resorption 
to the hypercalcaemia of PTH/PTH-rP induced 
disease increases with the circulating hormone 
level. Bone resorption is relatively unimportant 
in the majority of patients with mild disease and 
normal serum alkaline phosphatase levels whereas 
in patient 1, with severe osteoporosis  [Figure 1b] 
and massively elevated PTH and ALP levels, bone 
resorption must have been a major additional 
contributor to his hypercalcaemia. Both hormones 
also inhibit tubular phosphate reabsorption; urinary 
phosphate levels increase and serum levels decrease 
most obviously when measured in the fasting 
state. Examination of the bone profiles illustrates 
these points; the marked hypercalcaemia seen 
in patients 1 and 5, with raised PTH and PTH-rP 
levels respectively, was associated with low serum 
phosphate, but normal creatinine levels.
The other 3 patients had non-PTH/PTH-rP 
induced disease. This can occur in two situations; 
either excessive osteoclastic destruction of bone 
as occurs in myeloma, or hyperabsorption of 
intestinal calcium due to elevated circulating 
1,25(OH)2D levels.
1,6 In either situation, the 
body responds as though it is receiving a slow 
calcium infusion; endogenous PTH levels are 
suppressed and tubular calcium reabsorption 
reduced resulting in marked hypercalciuria. 
Unchecked hypercalciuria is nephrotoxic and 
results in a progressive fall in glomerular filtration 
rate (GFR) and rising creatinine levels. Because 
endogenous PTH levels are suppressed, tubular 
resorption of phosphate is increased and serum 
phosphate levels are normal or increased. These 
features are seen in Table 2 where the hypercalcaemia 
of patients 2, 3 and 4 was associated with normal 
phosphate and raised creatinine levels. As their 
skeletal radiographs were normal, hyperabsorption 
of calcium, and not increased osteoclastic resorption 
of bone, was correctly predicted to be the cause 
of the hypercalcaemia. This was later confirmed 
by finding raised circulating levels of 1,25(OH)2D 
Figure 4: Patient 4 - Renal biopsy showing a non-caseating 
granuloma consistent with sarcoidosis.
Figure 5: Patient 5 - Chest X-ray revealing bilateral lung 
metastases.
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in all 3 patients. Under normal circumstances, 
macrophages synthesise 1,25(OH)2D from 25OHD. 
This in turn stimulates the production and secretion 
of antimicrobial defensins.7 When macrophages are 
present in large numbers around inflammatory foci 
(e.g. tuberculosis8,9,10 or sarcoidosis11,12) or certain 
lymphomas,13,14,15 1,25(OH)2D spills over into the 
circulation, causing initially hypercalciuria, and 
later hypercalcaemia as renal function deteriorates 
and the absorbed calcium load cannot be excreted. 
At this point, the 24-hour urine calcium levels are 
often within the ‘normal’ range [Table 3].  Patient 4 
had sarcoidosis and myeloma, but the myeloma was 
not responsible for the hypercalcaemia16,17,18 as his 
haemoglobin and skeletal survey were normal and 
1,25OH2D levels elevated.
Conclusion
In the majority of patients, a fasting bone profile 
and serum creatinine level will distinguish 
between PTH and non-parathyroid causes of 
hypercalcaemia. Normal creatinine and low normal 
or low phosphate levels occur with raised PTH/
PTH-rP, whereas raised creatinine and normal 
or raised phosphate levels are seen in patients 
with non-parathyroid hypercalcaemia. Twenty-
four hour urine calcium levels should be measured 
in all patients with mild hyperparathyroidism; 
low values suggest a diagnosis of familial 
hypocalciuric hypercalcaemia and surgery is not 
indicated.
Patients with a parathyroid crisis should be 
treated medically for at least 2 weeks to avoid 
complications during surgery.
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Figure 6a, b & c: Patients 1, 2, 3 & 4 - Response to treatment of the underlying disease. 6a: Serum calcium; 6b: Serum 
1,25 dihydroxy vitamin D3; 6c: Serum creatinine
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